Overview

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients
Phase:
Phase 1
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.